Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
ETMarkets Smart Talk | India-Pak tensions seen as temporary ; focus on earnings, Gold allocation up to 20% : Vikram Kasat
1er/05/2025
Eternal to announce Q4 results today : Profit to take severe hit even as revenue growth seen strong
1er/05/2025
Stock Market Holidays 2025 : Are NSE, BSE open or closed on May 1 for Maharashtra Day ?
1er/05/2025
Overseas investors pull Rs 13,359 crore from Indian Bonds amid US yield surge and geopolitical tensions
1er/05/2025
TVS Motor enters FY26 on strong footing driven by rising EV adoption, premium product launches
1er/05/2025
IndusInd accounting lapse row : CEO's exit may point to more issues, hit recovery, margins
30/04/2025
